OSAKA, Japan & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, Protagonist Therapeutics and Takeda Pharmaceutical Company Limited (NYSE ...

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹ ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.

MANILA, Philippines — Takeda Healthcare Philippines on Thursday said that its voluntary withdrawal of its dengue applications in the US and Singapore has something to do with requested ...

Takeda-backed INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.

View the latest Takeda Pharmaceutical Co. Ltd. ADR (TAK) stock price, news, historical charts, analyst ratings and financial information from WSJ.

See the latest Takeda Pharmaceutical Co Ltd stock price (4502:XTKS), related news, valuation, dividends and more to help you make your investing decisions.

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control ...

Takeda Pharmaceutical Co. Ltd. ADR balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View TAK financial statements in full.